Fig. 5: Glutaminyl cyclase is involved in the trafficking of TRP1 to the cell surface which affects TRP-CD3-bispecific T cell therapy.
a KD calculation of TRP1 TA99 on B16F10 wildtype and QPCTL KO cells. ODE model fit for titration binding curves of WT and QPCTL KO conditions for the B16F10 cell line utilizing the full model in which KD values are estimated separately. b MFI of αTRP1 clone TA99 (1:50) followed by αmouse IgG APC (1:100) or αHIS PE (1:50) on grazoprevir treated HeLa cells expressing CAR-TRP1 in the presence or absence of 4 day treatment of 30 µM SEN177. Data represents the MFI, + standard deviation error bar. Unpaired T test was performed to assess the two groups (n = 3). c Percentage of CD8 + T-cells positive for the indicated markers that have been cocultured with B16F10 wildtype or QPCTL KO cells in the presence of 1, 0.1 or 0.01 ug/mL TRP1 TA99-CD3-bispecific antibody for 48 hours. Data represents the percentage, + standard deviation error bar. One-way Anova was performed to assess the groups (n = 3). Abbreviations: MFI, median fluorescent intensity; WT, wildtype; KO, knockout; PQ, PQ912; SEN, SEN177.
